Introduction {#S0001}
============

Radical cystectomy (RC) plus urinary diversion has long been the reference standard treatment for muscle-invasive bladder cancer (MIBC). However, RC is associated with high complication rates and can compromise quality of life as a result of long-term effects on urinary, gastrointestinal, and sexual function as well as changes in body image. Recently, various modalities of bladder-sparing approaches have been investigated and their benefits appreciated. Many of these protocols consist of transurethral resection of bladder tumor (TURBT) plus full-dose chemoradiotherapy (CRT) \[[@CIT0001]\]. Their limitations are 1) MIBC recurrence in the preserved bladder mainly due to subclinical residual disease in the original MIBC site and 2) potential lack of curative intervention to regional lymph nodes \[[@CIT0002], [@CIT0003]\]. Since 1997, we have carried out a selective bladder-sparing protocol incorporating consolidative partial cystectomy (PC) with pelvic lymph node dissection (PLND) after debulking TURBT and low-dose chemoradiotherapy (LCRT) \[[@CIT0002]--[@CIT0004]\]. Only patients who desire bladder preservation and who meet all of the PC criteria selectively undergo PC with PLND with curative intent \[[@CIT0002]--[@CIT0004]\]. The PC criteria include: 1) intravesically unifocal tumors (\< 25% of the bladder in area, excluding the bladder neck and trigone); 2) no involvement of the bladder neck or trigone; and 3) no residual tumor, or only small amounts of residual non-muscle-invasive bladder cancer (NMIBC) in the original MIBC site at restaging TURBT after LCRT. The PC with PLND could contribute to eradication of subclinical residual disease in original MIBC sites and micrometastases in pelvic lymph nodes and has been carried out using techniques of gasless single-port surgery, a minimally invasive surgery via a single port without CO~2~ gas insufflation \[[@CIT0002], [@CIT0005], [@CIT0006]\].

In 2011, we developed an affordable new three-dimensional (3D) vision system (RoboSurgeon system) with technical support from Sony Corporation, which is a combination of a high-definition 3D organic electroluminescent head-mounted display (HMD) (HMZ-T1; Sony Corporation, Tokyo, Japan) and a high-definition 3D endoscope (Shinko Optical, Tokyo, Japan, and Endoeye flex 3D deflectable videoscope, Olympus, Tokyo, Japan) and first applied this system to gasless single-port radical nephrectomy \[[@CIT0007]\]. Since 2013, the 3D HMD for medical use (HMM-3000MT; Sony Corporation, Tokyo, Japan) has been commercially available and we have adopted it. This system provides surgeons with high-quality 3D imagery right before their eyes, regardless of head position, and direct vision is readily available by glancing downward. Wearing the HMD, the lead surgeon and the assistants can simultaneously and continuously monitor the same image displayed by the HMD. Furthermore, this system is equipped with a 'Picture in Picture' feature, which enables a second image (such as from cystoscopy) to appear as a window while the image from the laparoscopy is kept as the main image. Each participant can independently rearrange the images comprising the composite image displayed on his HMD depending on the surgical step. The excellence of the HMD as a personal imaging monitoring system led us to apply this system to other gasless single-port procedures. Here, we present 5 cases of patients with MIBC undergoing RoboSurgeon gasless single-port partial cystectomy with a technique utilizing both an intravesical and extravesical approach.

Case reports {#S0002}
============

Surgical technique {#S20003}
------------------

Informed consent was obtained after a complete description of the various surgical procedures, including the gasless single-port surgery using the RoboSurgeon system, which was carried out with the approval of our university\'s ethics committee. All procedures were carried out by a surgeon who was experienced in gasless single-port surgery. The techniques of gasless single-port surgery have been presented previously \[[@CIT0005], [@CIT0006]\].

An outline of the surgery is shown in [Figure 1](#F0001){ref-type="fig"}. While under general anesthesia, the patient is placed in the lithotomy position. All surgeons wear an HMD\*\*1\*\* ([Photo 1](#F0002){ref-type="fig"}). A lower abdominal midline incision of around 4 cm is made and a single port is prepared by placement of an Alexis wound retractor (Applied Medical, Irvine, CA, USA). All devices, including a high-definition 3D endoscope, are inserted through the single port. All surgeons then begin to view the 3D imagery via the HMD. Whenever the surgeon receives the devices and inserts them through the port, the angle of sight is moved downward to obtain direct vision. Immediately after device insertion, every maneuver is carried out using a clear 3D image of the device which appears on the display. The 'Picture in Picture' feature is used to simultaneously show both images of the laparoendoscope and cystoscope ([Photo 2](#F0003){ref-type="fig"}).

![Outline of RoboSurgeon gasless single-port partial cystectomy](WIITM-9-23267-g001){#F0001}

![Photograph of RoboSurgeon gasless laparoendoscopic single-port partial cystectomy. All surgeons, including the TUR surgeon, wear a head-mounted display (**A**). After the intravesical approach is finished, the remaining procedures are carried out extravesically (**B**)](WIITM-9-23267-g002){#F0002}

![Intravesical approach. The Collins incision is deepened along the proposed resection margin through the serosa until full thickness is achieved. The TUR surgeon carries out this procedure while viewing the cystoscopic image as the main image and the laparoendoscopic image as the second image of the 'Picture in Picture' on the HMD (**A**), while the other surgeons view the laparoendoscopic image as the main image and the cystoscopic image as the second image to confirm that there is no inadvertent injury to surrounding structures or tissues (**B**). The TUR site can be easily recognized from outside of the bladder by the transmitted light of cystoscopy passing through the bladder wall](WIITM-9-23267-g003){#F0003}

Partial cystectomy is typically performed using an extraperitoneal approach. After dissection of the space of Retzius and exposure of the anterior surface of the bladder, the Iglesias resectoscope is placed into the urethra and cystopanendoscopy is performed. On cystoscopy, their original MIBC site typically appears like a scar because these patients must meet the PC criteria that there is no residual tumor or only small amounts of residual NMIBC in the original MIBC site after LCRT. Then, under laparoendoscopy, the bladder is freed necessarily and sufficiently beyond the site of the tumor, which can easily be recognized from outside of the bladder by the transmitted light of the cystoscope passing through the bladder wall ([Photo 2](#F0003){ref-type="fig"}). For tumors located at the dome, the peritoneum is opened. The fat and the peritoneum over the site of the tumor is left attached to the bladder. Under cystoscopy, the proposed excision line around the tumor scar with a margin of approximately 1 cm is scored on the bladder surface using a Collins knife electrode. Next, the Collins incision is deepened along the proposed resection margin through the serosa until full thickness is achieved ([Photo 2](#F0003){ref-type="fig"}). The TUR surgeon carries out this procedure while viewing the cystoscopic image as the main image and the laparoendoscopic image as the second image of the 'Picture in Picture' on the HMD. Other surgeons see the laparoendoscopic image as the main image and the cystoscopic image as the second image to confirm that there is no inadvertent injury to the surrounding structures or tissues. Next, the remaining procedures are performed extravesically while viewing the laparoendoscopic image. The bladder wall is divided along the intravesically made margin line by electric cautery ([Photo 3A](#F0004){ref-type="fig"}), and the entire lesion is circumcised and removed en bloc with the perivesical fat and overlying peritoneum if necessary. A frozen section of the edge is obtained in preparation to resect more of the wall.

![Photo 3. After the intravesical approach, the bladder wall is extravesically divided along the cystoscopically made margin line (arrow) by electric cautery while viewing the laparoendoscopic image (**A**). The bladder is closed in two layers (**B**)](WIITM-9-23267-g004){#F0004}

The PLND was performed during the frozen section pathology examination. The template for PLND included the external iliac artery and the internal obturator muscle laterally, the internal iliac artery medially, the bifurcation of the common iliac artery cranially, and the origin of the epigastric vessels caudally. Finally, the bladder is closed in two layers using a 3-0 Vicryl suture ([Photo 3B](#F0004){ref-type="fig"}). The closing site is observed under cystoscopy. Perivesical drains were placed. The abdominal wall was then closed. Postoperatively, the urethral catheter is left in place for 7 to 10 days.

Results {#S20004}
-------

While carrying out gasless single-port partial cystectomy, the system provided the surgeon with excellent 3D imagery of the operative field. During the surgery, none of the participants experienced any HMD-related adverse effects or reported any discomfort. All five procedures were successfully completed without intraoperative complications ([Table I](#T0001){ref-type="table"}). In 1 patient (\#3), who had a tumor located at the dome, the peritoneum was opened and the entire lesion was removed en bloc with the overlying peritoneum. Frozen section pathology reported atypical urothelial cells in 1 patient (\#2), who had more of the bladder wall resected. The final pathological diagnosis was no cancer cells. Operating times were 215 to 311 (median: 249) min and estimated blood losses were 10 to 125 (median: 50) ml. All patients had the urethral catheter removed within 10 days. Postoperative recovery was uneventful except for 1 patient (\#3) who developed lymphorrhea that required drain reinsertion.

###### 

Clinical features of patients undergoing RoboSurgeon partial cystectomy

  Parameter                                           Patient 1                                                        Patient 2                                                          Patient 3                                                        Patient 4                                                        Patient 5
  --------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------
  Gender                                              Male                                                             Male                                                               Male                                                             Male                                                             Male
  Age \[years\]                                       56                                                               72                                                                 74                                                               73                                                               79
  Diagnosis                                           High-grade muscle invasive urothelial carcinoma (cT2 pT2 N0M0)   High-grade muscle invasive urothelial carcinoma (cT3b pT2≤ N0M0)   High-grade muscle invasive urothelial carcinoma (cT2 pT2 N0M0)   High-grade muscle invasive urothelial carcinoma (cT2 pT2 N0M0)   High-grade muscle invasive urothelial carcinoma (cT2 pT2 N0M0)
  Location                                            Right lateral wall                                               Left lateral wall                                                  Dome                                                             Left lateral wall                                                Left lateral wall
  Approach                                            Extraperitoneal                                                  Extraperitoneal                                                    Extraperitoneal and transperitoneal                              Extraperitoneal                                                  Extraperitoneal
  Operative time \[min\]                              222                                                              311[\*](#TF0001){ref-type="table-fn"}                              251                                                              215                                                              249
  Estimated blood loss \[ml\]                         70                                                               30                                                                 125                                                              10                                                               50
  Intraoperative complications                        None                                                             None                                                               None                                                             None                                                             None
  Postoperative complications                         None                                                             None                                                               Lymphorrhea requiring drain insertion                            None                                                             None
  Final pathology[\#](#TF0002){ref-type="table-fn"}   No viable cancer cells in PC and PLND specimens                  No viable cancer cells in PC and PLND specimens                    No viable cancer cells in PC and PLND specimens                  No viable cancer cells in PC and PLND specimens                  No viable cancer cells in PC and PLND specimens

A frozen section of the edge showed atypical urothelial cells, and more of the bladder wall was resected. The final pathological diagnosis was no cancer cells.

PC -- partial cystectomy, PLND -- pelvic lymph node dissection

Discussion {#S0005}
==========

The da Vinci Surgical Robotic System (Intuitive Surgical, Sunnyvale, CA, USA) is increasingly being used to perform urologic surgery. Robotic technology provides additional dimensions to laparoscopy by adding 3D observation, improved ergonomic stabilization of surgical movements, and ease of intracorporeal suturing. This system has several aspects that need to be improved for structural or financial reasons, such as a large imaging console located some distance from the patient, a lack of tactile feedback and extremely high equipment and running costs.

To preserve the benefits and mitigate the defects of the systems, we recently developed an affordable new 3D vision system (RoboSurgeon System), which is a combination of a high-definition 3D organic electroluminescent HMD and a high-definition 3D endoscope. We first applied this system to gasless single-port radical nephrectomy \[[@CIT0007]\]. We subsequently applied it to various urologic procedures, including transurethral resection of the prostate \[[@CIT0008]\]. This is the first study to use this system in gasless laparoendoscopic single-port partial cystectomy. The high-definition 3D endoscope, which enables clear depth perception, is beneficial for complex tasks during the surgery. Using a 3D HMD instead of a standard 3D TV display, surgeons can rely on natural lines of sight, with the head at any desired angle of rotation or inclination, which minimizes fatigue. The surgeon wearing the HMD carries out the surgery while touching and looking at the patient and receiving tactile feedback through the device.

The da Vinci Surgical Robotic System was recently reported to have been applied to partial cystectomy not only in patients with benign lesions, such as bladder pheochromocytoma and leiomyoma, but also in selected patients with bladder cancer \[[@CIT0009], [@CIT0010]\]. For example, Allaparthi *et al*. reported 3 cases of bladder cancer patients who underwent transperitoneal robotic partial cystectomy \[[@CIT0009]\]. The robotic partial cystectomy was completed in all 3 patients without the need for open conversion. However, 1 patient was readmitted and underwent small bowel resection secondary to bowel obstruction. One of the possible advantages of our RoboSurgeon partial cystectomy is that it is typically performed using an extraperitoneal approach, which is unlikely to be associated with bowel complications. Even when the tumor is located at the dome, the opening of the peritoneum is very restricted.

RoboSurgeon gasless single-port partial cystectomy is carried out with a technique that employs both an intravesical and extravesical approach, which we believe has some advantages. First, this prevents overdissection of the bladder. The site of the tumor can be easily recognized from the outside of the bladder by the transmitted light of the cystoscope passing through the bladder wall. Second and most importantly, the margin can accurately be identified under cystoscopy. After the intravesical excision, extravesical excision of the remaining tissue can easily be performed. In our system, each participant can independently rearrange the images comprising the 'Picture in Picture' image depending on the surgical step, enabling the surgery to be performed easily and safely. During the intravesical approach, the TUR surgeon sees the cystoscopic image as the main image, while the other surgeons see the laparoendoscopic image as the main image to confirm that there is no inadvertent injury to surrounding structures or tissues.

In our series, none of the patients had viable cancer cells in either PC or PLND specimens in the final pathology. We do not consider that this means that PC with PLND was not necessary in these patients. As mentioned in the introduction, PC with PLND could contribute to eradication of subclinical residual disease in original MIBC sites and micrometastases in pelvic lymph nodes \[[@CIT0002]--[@CIT0004]\]. In our previous series of 46 patients undergoing PC with PLND in our bladder preservation protocol, none developed MIBC recurrence in the preserved bladder or pelvic lymph node recurrence \[[@CIT0002], [@CIT0003]\].

Conclusions {#S0006}
===========

This study demonstrates the technical feasibility and utility of gasless laparoendoscopic single-port partial cystectomy using our 3D HMD system. A study consisting of a larger number of patients and longer follow-up is needed to validate the utility and establish the oncological outcomes of this technique in patients with bladder cancer.
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